Ironwood Pharmaceuticals IRWD Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's short- and long-term operating lease liabilities?
- Ironwood Pharmaceuticals (IRWD) reported short- and long-term operating lease liabilities of -$621K in Q1 2026.
- How has Ironwood Pharmaceuticals's short- and long-term operating lease liabilities changed year-over-year?
- Ironwood Pharmaceuticals's short- and long-term operating lease liabilities decreased by 8.6% year-over-year, from -$572K to -$621K.
- What is the long-term trend for Ironwood Pharmaceuticals's short- and long-term operating lease liabilities?
- Over 4 years (2021 to 2025), Ironwood Pharmaceuticals's short- and long-term operating lease liabilities has grown at a 6.6% compound annual growth rate (CAGR), from -$1.84M to -$2.37M.